Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Single-center Phase I Study on the Safety, Tolerability, and Pharmacokinetics of Enterovirus-based EM-I-2024 in Patients With a Histologically Confirmed Diagnosis of a Solid Tumor

NCT07584668 is registered in ClinicalTrials.gov with National Medical Research Radiological Centre of the Ministry of Health of Russia as lead sponsor.

NCT NCT07584668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07584668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Single-center Phase I Study on the Safety, Tolerability, and Pharmacokinetics of Enterovirus-based EM-I-2024 in Patients With a Histologically Confirmed Diagnosis of a Solid Tumor
Lead sponsor
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 30, 2025
Completion date
February 28, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

assess the safety and tolerability of various doses and dosing schedules of enteromix in patients with a histologically confirmed solid tumor